Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one

Efficacy of intravitreal bevacizumab in the treatment of refractory central serous chorioretinopathy

Case Report Sample Work

The use of Intravitreal Bevacizumab, an anti-VEGF medication, for treating Refractory Central Serous Chorioretinopathy (CSCR), a condition where fluid accumulates under the retina, potentially leading to vision loss. Traditional treatment methods may not always be effective for CSCR, making it a challenging condition to treat. The document likely presents a case report detailing the use of Bevacizumab in a patient resistant to standard therapies, highlighting its potential efficacy in treating refractory CSCR.

A single-patient ophthalmology report on an off-label injection

This case report sample describes the treatment of central serous chorioretinopathy (CSC) that did not settle with conservative management, using a single intravitreal injection of bevacizumab (IVB). Bevacizumab is an anti-VEGF antibody widely used in ophthalmology for neovascular conditions, but its use in CSC is off-label and the evidence for it is mixed. A carefully documented case adds a data point to that discussion.

The report is aimed at ophthalmologists and retina specialists, and at journals with case report sections in retinal disease. It is deliberately brief, which makes it a good model for authors preparing a short clinical communication. Within two pages it carries an abstract, a narrative of the clinical course, an outcome section, a discussion, a conclusion, a figure and references, showing how much a compact report can hold when each section keeps to its purpose.

Fluid beneath the macula and the problem of chronic CSC

In CSC, fluid collects beneath the neurosensory retina, usually at the macula, producing blurred or distorted central vision. It is most often seen in working-age men and has well-recognised associations with corticosteroid exposure and abnormal choroidal permeability. Many acute episodes resolve on their own, which is why observation is a common first step. When fluid persists, the condition can lead to lasting visual loss, and treatment options include photodynamic therapy, laser approaches and oral mineralocorticoid receptor antagonists.

The rationale for anti-VEGF treatment in CSC is less settled than in neovascular disease, and published results vary. The sample's own reference list reflects this context, citing a review of CSC, an earlier report of intravitreal bevacizumab in chronic CSC and a study of photodynamic therapy for focal leaks.

Tracing the escalation from observation to injection

The report sets out a logical treatment sequence for a 40-year-old man:

  1. Observation for six months: symptoms fluctuated, with brief improvements followed by worsening and a gradual decline in visual acuity.
  2. Oral spironolactone for three months: no meaningful improvement, and continued serous detachment on examination.
  3. Single IVB injection: chosen because of bevacizumab's established use in other neovascular eye conditions, after informed consent covering risks and benefits.
  4. Follow-up: visits at one week and one month after injection, with attention to visual acuity and retinal anatomy, and advice to report any adverse effects promptly.

A composite figure of retinal imaging accompanies the narrative, giving readers visual evidence alongside the measurements. Each step in the sequence is justified before the next is introduced, so a reviewer can see that the injection was offered only after less invasive options had been tried for a reasonable period. That ordering also answers a question editors frequently ask of off-label treatment reports: why this option, and why at this point in the course of the disease?

Reading the logMAR and macular thickness results

The outcome section uses two standard measures. Best-corrected visual acuity improved from 0.6 to 0.4 logMAR at two months and to 0.3 logMAR at six months; on the logMAR scale a lower value means better vision. Central macular thickness fell from 370 µm at baseline to 210 µm at six months, and no recurrence of serous detachment was seen during follow-up.

The discussion and conclusion keep these findings in proportion. They describe IVB as a potential alternative for refractory cases and call for larger, controlled studies to establish efficacy and safety, which is the appropriate level of claim for a single case in a condition that can improve spontaneously. Reporting both a functional measure (visual acuity) and an anatomical one (macular thickness) is also good practice, because the two do not always change together and reviewers look for agreement between them.

Strengthening a short retinal case report for submission

Authors adapting this format should follow the CARE checklist, described in Pubrica's guide to CARE guidelines, paying attention to items that retina reviewers often request: the imaging modalities used to confirm the diagnosis, whether choroidal neovascularisation was excluded, the dose of bevacizumab, any corticosteroid history and the length of follow-up. Stating clearly that the use was off-label, and that informed consent was obtained, is also expected.

The numbered reference style suits Vancouver-based ophthalmology journals, and Pubrica's journal manuscript formatting service can adapt it to a specific journal. For help turning a clinic case into a manuscript, see the case report writing service. This page presents a writing sample and does not offer treatment advice.

Questions about this sample

What does refractory mean in this CSC case report?

It means the subretinal fluid did not resolve with earlier management. In this sample the patient was observed for six months and then took oral spironolactone for three months, yet serous detachment persisted and vision declined, so intravitreal bevacizumab was offered as an alternative.

How should the logMAR values in this report be interpreted?

On the logMAR scale, lower numbers indicate better visual acuity, and 0.0 corresponds to standard 6/6 vision. The patient's improvement from 0.6 to 0.4 logMAR at two months and to 0.3 logMAR at six months therefore represents a gain in best-corrected vision.

Is bevacizumab an approved treatment for central serous chorioretinopathy?

Bevacizumab is used off-label in ophthalmology, and its role in CSC is not established. The sample itself presents the result as promising but calls for larger controlled studies. Case reports describing off-label treatment should state this clearly and document informed consent.

What outcome measures does the report use?

It reports best-corrected visual acuity in logMAR units and central macular thickness in micrometres, measured at baseline and during follow-up, along with whether serous detachment recurred. Macular thickness fell from 370 µm to 210 µm at six months, with no recurrence observed.

pubrica services with experts

Research your Services with our experts

Delivered on-time or your money back

Give yourself the academic edge today

Each order includes

  • On-time delivery or your money back
  • A fully qualified writer in your subject
  • In-depth proofreading by our Quality Control Team
  • 100% confidentiality, the work is never re-sold or published
  • Standard 7-day amendment period
  • A paper written to the standard ordered
  • A detailed plagiarism report
  • A comprehensive quality report

Enquire Now

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.